Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update - CNBC

Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update    CNBC Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns    statnews.com Why This Biotech Plummeted Despite Its 'Best-Case' Study    Investor's Business Daily Jefferies downgrades Abivax stock rating on cancer signal concerns    Investing.com Abivax Says Ulcerative Colitis Drug Met Goal in Late-Stage Trial    Bloomberg.com

Original source: Google News